CEBPA and leukemia: Patients with CEBPA-associated familial AML with a cured initial presentation are at high risk of developing additional independent leukemic episodes in addition to the risk of relapse from a pre-existing clone; the clinical observation that AML patients with CEBPA variants are more likely to develop a secondary leukemia despite their favorable prognosis is likely due to this pattern of progression [37].